HUE056334T2 - Izoxazolil-lal szubsztituált benzimidazolok - Google Patents

Izoxazolil-lal szubsztituált benzimidazolok

Info

Publication number
HUE056334T2
HUE056334T2 HUE16718863A HUE16718863A HUE056334T2 HU E056334 T2 HUE056334 T2 HU E056334T2 HU E16718863 A HUE16718863 A HU E16718863A HU E16718863 A HUE16718863 A HU E16718863A HU E056334 T2 HUE056334 T2 HU E056334T2
Authority
HU
Hungary
Prior art keywords
substituted benzimidazoles
isoxazolyl substituted
isoxazolyl
benzimidazoles
substituted
Prior art date
Application number
HUE16718863A
Other languages
English (en)
Inventor
Neil Anthony Pegg
David Michel Adrien Taddei
Stuart Thomas Onions
Eric Sing Yuen Tse
Richard James Brown
David Kenneth Mycock
David Cousin
Anil Patel
Original Assignee
Cellcentric Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Cellcentric Ltd filed Critical Cellcentric Ltd
Publication of HUE056334T2 publication Critical patent/HUE056334T2/hu

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
HUE16718863A 2015-04-20 2016-04-20 Izoxazolil-lal szubsztituált benzimidazolok HUE056334T2 (hu)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
GBGB1506658.2A GB201506658D0 (en) 2015-04-20 2015-04-20 Pharmaceutical compounds

Publications (1)

Publication Number Publication Date
HUE056334T2 true HUE056334T2 (hu) 2022-02-28

Family

ID=53298840

Family Applications (1)

Application Number Title Priority Date Filing Date
HUE16718863A HUE056334T2 (hu) 2015-04-20 2016-04-20 Izoxazolil-lal szubsztituált benzimidazolok

Country Status (9)

Country Link
US (1) US10118920B2 (hu)
EP (1) EP3286183B1 (hu)
JP (1) JP6871864B2 (hu)
CN (1) CN107750249A (hu)
DK (1) DK3286183T3 (hu)
ES (1) ES2888473T3 (hu)
GB (1) GB201506658D0 (hu)
HU (1) HUE056334T2 (hu)
WO (1) WO2016170324A1 (hu)

Families Citing this family (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB201506660D0 (en) 2015-04-20 2015-06-03 Cellcentric Ltd Pharmaceutical compounds
US10836742B2 (en) 2015-08-11 2020-11-17 Neomed Institute N-substituted bicyclic lactams, their preparation and their use as pharmaceuticals
KR20180039117A (ko) 2015-08-11 2018-04-17 네오메드 인스티튜트 아릴-치환된 디히드로퀴놀리논, 그의 제조법 및 제약으로서의 그의 용도
EP3334719B1 (en) 2015-08-12 2021-09-15 Neomed Institute Substituted benzimidazoles, their preparation and their use as pharmaceuticals
WO2017066876A1 (en) 2015-10-21 2017-04-27 Neomed Institute Substituted imidazopyridines, their preparation and their use as pharmaceuticals
WO2017127930A1 (en) 2016-01-28 2017-08-03 Neomed Institute Substituted [1,2,4]triazolo[4,3-a]pyridines, their preparation and their use as pharmaceuticals
GB201617630D0 (en) 2016-10-18 2016-11-30 Cellcentric Ltd Pharmaceutical compounds
GB201617627D0 (en) * 2016-10-18 2016-11-30 Cellcentric Ltd Pharmaceutical compounds
MA50250A (fr) 2017-09-15 2020-07-22 Forma Therapeutics Inc Compositions de tétrahydroimidazo quinoléine utilisées en tant qu'inhibiteurs de cbp/p300
KR20210003764A (ko) 2018-03-29 2021-01-12 보드 오브 리전츠 더 유니버시티 오브 텍사스 시스템 전사 활성화 단백질의 이미다조피페라진 억제제
WO2019195846A1 (en) 2018-04-06 2019-10-10 Board Of Regents, The University Of Texas System Imidazopiperazinone inhibitors of transcription activating proteins
GB201806320D0 (en) * 2018-04-18 2018-05-30 Cellcentric Ltd Process
SG11202012767UA (en) 2018-06-29 2021-01-28 Forma Therapeutics Inc Inhibiting creb binding protein (cbp)
CN112574189B (zh) * 2019-09-27 2024-05-31 海创药业股份有限公司 一种ep300/cbp抑制剂
CN112574191B (zh) * 2019-09-29 2024-01-23 南京圣和药业股份有限公司 异噁唑杂环类化合物及其应用
BR112022025911A2 (pt) 2020-06-25 2023-01-10 Tolremo Therapeutics Ag Combinação de um inibidor de bromodomínio de cbp/p300 e um inibidor de egfr para uso no tratamento de um cpcnp com egfr mutante
CN115996717A (zh) 2020-06-25 2023-04-21 托雷莫治疗股份公司 用于治疗癌症的cbp/p300溴结构域抑制剂和kras抑制剂的组合
US11795168B2 (en) 2020-09-23 2023-10-24 Forma Therapeutics, Inc. Inhibiting cyclic amp-responsive element-binding protein (CREB) binding protein (CBP)
US11801243B2 (en) 2020-09-23 2023-10-31 Forma Therapeutics, Inc. Bromodomain inhibitors for androgen receptor-driven cancers
CN112250672B (zh) * 2020-10-21 2022-06-21 清华大学深圳国际研究生院 一种核苷碱基衍生物及其制备方法和应用
CN116670129A (zh) * 2020-12-31 2023-08-29 南京明德新药研发有限公司 苯并咪唑类化合物及其应用

Family Cites Families (113)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE1670684A1 (de) 1966-04-01 1970-12-03 Hoechst Ag Verfahren zur Herstellung von basisch substituierten Bis-benzimidazol-derivaten
WO1990012321A1 (en) 1989-03-31 1990-10-18 The Cancer Institute Board Halogenated dna ligand radiosensitisers for cancer therapy
US5667975A (en) 1994-05-06 1997-09-16 The University Of North Carolina Method of fluorescent detection of nucleic acids and cytoskeleton elements using bis-dicationic aryl furans
EP0777656B1 (en) 1994-08-26 2004-04-14 Auckland Division Cancer Society Of New Zealand (Incorporated) Novel dna-targeted alkylating agents
US5668167A (en) 1995-06-07 1997-09-16 Duke University Methods of treating microbial infections
US5643935A (en) 1995-06-07 1997-07-01 The University Of North Carolina At Chapel Hill Method of combatting infectious diseases using dicationic bis-benzimidazoles
AUPN449295A0 (en) 1995-07-28 1995-08-24 Inner And Eastern Health Care Network, The Radioprotectors
US5770617A (en) 1996-03-20 1998-06-23 Rutgers, The State University Of New Jersey Terbenzimidazoles useful as antifungal agents
EP0988037A1 (en) 1997-02-05 2000-03-29 Board Of Regents, The University Of Texas System Porphyrin compounds as telomerase inhibitors
US5935982A (en) 1997-02-28 1999-08-10 The University Of North Carolina At Chapel Hill Methods of treating retroviral infection and compounds useful therefor
IL137351A0 (en) 1998-02-12 2001-07-24 Univ Rutgers Heterocyclic topoisomerase poisons
TWI244481B (en) 1998-12-23 2005-12-01 Pfizer 3-azabicyclo[3.1.0]hexane derivatives useful in therapy
JP4507026B2 (ja) 1999-04-06 2010-07-21 東洋紡績株式会社 ハレーション防止用組成物およびそれを用いた感光性樹脂積層体
MXPA01011001A (es) 1999-04-30 2003-06-24 Slil Biomedical Corp Quinonas novedosas como terapias para enfermedades.
IL149153A0 (en) 1999-11-05 2002-11-10 Aventis Pharma Sa Oligobenzimidazole derivatives and their use as dna transfection agents
US6613787B2 (en) 1999-12-20 2003-09-02 The University Of North Carolina At Chapel Hill Compounds that exhibit specific molecular recognition of mixed nucleic acid sequences and bind in the DNA minor groove as a dimer
YU54202A (sh) 2000-01-18 2006-01-16 Agouron Pharmaceuticals Inc. Jedinjenja indazola, farmaceutske smeše i postupci za stimulisanje i inhibiranje ćelijske proliferacije
GB0011092D0 (en) 2000-05-08 2000-06-28 Black James Foundation Gastrin and cholecystokinin receptor ligands (III)
DE60222899T2 (de) 2001-01-13 2008-08-14 Auburn University, Auburn Verbindungen, verfahren und zusammensetzungen für die behandlung von infektionen mit dem rinderdiarrhö-virus (bvdv) und dem hepatitis-c-virus (hcv)
US6709929B2 (en) 2001-06-25 2004-03-23 North Carolina State University Methods of forming nano-scale electronic and optoelectronic devices using non-photolithographically defined nano-channel templates
EP1420773A1 (en) 2001-08-31 2004-05-26 Neurochem (International) Limited Amidine derivatives for treating amyloidosis
WO2003045929A1 (fr) 2001-11-26 2003-06-05 Takeda Chemical Industries, Ltd. Derive bicyclique, procede de production de ce derive et utilisation correspondante
US7163952B2 (en) 2001-12-03 2007-01-16 Japan Tobacco Inc. Azole compound and medicinal use thereof
JP2004024114A (ja) 2002-06-26 2004-01-29 Shigeori Takenaka 電気化学的二本鎖ｄｎａ検出試薬としての新規インターカレータ
WO2004014881A2 (en) 2002-08-09 2004-02-19 Astra Zeneca Ab '1,2,4'oxadiazoles as modulators of metabotropic glutamate receptor-5
US7825132B2 (en) 2002-08-23 2010-11-02 Novartis Vaccines And Diagnostics, Inc. Inhibition of FGFR3 and treatment of multiple myeloma
US20050256157A1 (en) 2002-08-23 2005-11-17 Chiron Corporation Combination therapy with CHK1 inhibitors
BR0313743A (pt) 2002-08-23 2005-07-05 Chiron Corp Benzimidazol quinolinonas e usos destas
AU2004261667A1 (en) 2003-08-01 2005-02-10 Genelabs Technologies, Inc. Bicyclic imidazol derivatives against Flaviviridae
WO2005033065A1 (en) 2003-09-05 2005-04-14 University Of North Carolina At Chapel Hill Novel amidine compounds for treating microbial infections
KR101167573B1 (ko) 2003-11-07 2012-07-30 노바티스 백신즈 앤드 다이아그노스틱스 인코포레이티드 개선된 약학적 성질을 갖는 퀴놀리논 화합물의 약학적으로허용가능한 염
CN100567270C (zh) 2004-02-19 2009-12-09 万有制药株式会社 磺酰胺衍生物
US8097238B2 (en) 2004-02-27 2012-01-17 Peter Maccallum Cancer Institute Cell targeting conjugates
US20070276020A1 (en) 2004-03-08 2007-11-29 Boykin David W Dicationic Compounds For Activity Against Trichomonas Vaginalis
EP1791835A2 (en) 2004-09-09 2007-06-06 Astellas Pharma Inc. Thiazole derivatives having vap-1 inhibitory activity
AU2005287170B2 (en) 2004-09-17 2012-03-29 Exelixis, Inc Pyrazole kinase modulators and methods of use
WO2006130673A1 (en) 2005-05-31 2006-12-07 Janssen Pharmaceutica, N.V. 3-benzoimidazolyl-pyrazolopyridines useful in treating kinase disorders
CA2617123C (en) 2005-08-12 2015-05-26 United States Government As Represented By The Secretary Of The United States Army And The U.S. Army Medical Research & Materiel Command Broad spectrum antibacterial compounds
US7691885B2 (en) 2005-08-29 2010-04-06 Vertex Pharmaceuticals Incorporated Pyridones useful as inhibitors of kinases
ATE533485T1 (de) 2005-10-31 2011-12-15 Merck Sharp & Dohme Cetp-inhibitoren
ES2550589T3 (es) 2006-12-21 2015-11-10 Peter Maccallum Cancer Institute Compuestos radioprotectores y métodos relacionados
WO2009005551A2 (en) 2007-03-27 2009-01-08 Paratek Pharmaceuticals, Inc. Transcription factor modulating compounds and methods of use thereof
GB0707934D0 (en) 2007-04-24 2007-05-30 Glaxo Group Ltd Chemical compounds
US7662526B2 (en) 2007-05-04 2010-02-16 Xerox Corporation Photoconductors
US8198307B2 (en) 2007-05-11 2012-06-12 Korea Research Institute Of Chemical Technology Imidazole derivatives having aryl piperidine substituent, method for preparation thereof and pharmaceutical compositions containing same
JP2009005594A (ja) 2007-06-26 2009-01-15 Kyoto Univ 遺伝子診断機能性蛍光色素の製造方法
WO2009105140A2 (en) 2007-12-11 2009-08-27 Viamet Pharmaceuticals, Inc. Metalloenzyme inhibitors using metal binding moieties in combination with targeting moieties
EP2240491B1 (en) 2008-01-09 2015-07-15 Amura Therapeutics Limited TETRAHYDROFURO(2,3-b)PYRROL-3-ONE DERIVATIVES AS INHIBITORS OF CYSTEINE PROTEINASES
PT2373172E (pt) 2008-12-03 2013-10-21 Presidio Pharmaceuticals Inc Inibidores de ns5a de hcv
WO2010065668A1 (en) 2008-12-03 2010-06-10 Presidio Pharmaceuticals, Inc. Inhibitors of hcv ns5a
WO2010075376A2 (en) 2008-12-23 2010-07-01 Abbott Laboratories Anti-viral compounds
EP2398474A4 (en) 2009-02-23 2012-12-05 Presidio Pharmaceuticals Inc HCV NS5A SHEMMER
KR101219487B1 (ko) 2009-03-03 2013-01-15 덕산하이메탈(주) 비스벤조이미다졸 화합물 및 이를 이용한 유기전기소자, 그단말
US8748618B2 (en) 2009-05-13 2014-06-10 University Of Virginia Patent Foundation Inhibitors of inv(16) leukemia
DK2455376T3 (en) 2009-06-11 2015-03-02 Abbvie Bahamas Ltd Heterocyclic compounds as inhibitors of hepatitis C virus (HCV)
US8937150B2 (en) 2009-06-11 2015-01-20 Abbvie Inc. Anti-viral compounds
WO2010148006A1 (en) 2009-06-16 2010-12-23 Enanta Pharmaceuticals, Inc. Hepatitis c virus inhibitors
US8221737B2 (en) 2009-06-16 2012-07-17 Enanta Pharmaceuticals, Inc. Hepatitis C virus inhibitors
US20120142672A1 (en) 2009-07-13 2012-06-07 Tatsuki Koike Heterocyclic compound and use thereof
US9072761B2 (en) 2009-08-14 2015-07-07 Clemson University Research Foundation (Curf) Methods and compositions related to viral inhibition
WO2011031904A1 (en) 2009-09-11 2011-03-17 Enanta Pharmaceuticals, Inc Hepatitis c virus inhibitors
CN104530079B (zh) 2009-12-18 2017-10-20 北京凯因科技股份有限公司 C型肝炎病毒复制的新型抑制剂
US8933110B2 (en) 2010-01-25 2015-01-13 Enanta Pharmaceuticals, Inc. Hepatitis C virus inhibitors
WO2011099832A2 (en) 2010-02-12 2011-08-18 Crystalgenomics, Inc. Novel benzimidazole compound, preparation method thereof and pharmaceutical composition comprising the same
CA2794145A1 (en) 2010-03-24 2011-09-29 Vertex Pharmaceuticals Incorporated Analogues for the treatment or prevention of flavivirus infections
TW201139438A (en) 2010-03-24 2011-11-16 Vertex Pharma Analogues for the treatment or prevention of flavivirus infections
MX2012010919A (es) 2010-03-24 2013-02-01 Vertex Pharma Analogos para el tratamiento o prevencion de infecciones por flavivirus.
WO2011151618A2 (en) 2010-06-01 2011-12-08 Summit Corporation Plc Compounds for the treatment of clostridium difficile-associated disease
AU2011308256B2 (en) 2010-09-28 2015-08-20 Daewoong Pharmaceutical Co., Ltd. Novel method of preparing benzoimidazole derivatives
WO2012044567A2 (en) 2010-09-30 2012-04-05 Merck Sharp & Dohme Corp. Imidazole derivatives
MX2013006951A (es) 2010-12-16 2013-10-03 Abbvie Inc Compuestos antivirales.
WO2012123298A1 (en) 2011-03-11 2012-09-20 F. Hoffmann-La Roche Ag Antiviral compounds
JP2014509660A (ja) 2011-04-01 2014-04-21 ユニバーシティ・オブ・ユタ・リサーチ・ファウンデイション ＰＤＫ１キナーゼの阻害剤としての置換３−（１Ｈ−ベンゾ｛ｄ｝イミダゾール−２−イル）−１Ｈ−インダゾール類似体
US8785436B2 (en) 2011-05-16 2014-07-22 Hoffmann-La Roche Inc. 1,3-oxazines as BACE 1 and/or BACE2 inhibitors
WO2012167053A1 (en) 2011-06-01 2012-12-06 Janus Biotherapeutics, Inc. Novel immune system modulators
EA023045B1 (ru) 2011-07-15 2016-04-29 Янссен Фармасьютикалз, Инк. Новые замещенные производные индола в качестве модуляторов гамма-секретазы
WO2013036749A1 (en) 2011-09-07 2013-03-14 University Of Kansas Hcv helicase inhibitors and methods of use thereof
WO2013049567A1 (en) 2011-09-29 2013-04-04 The Broad Institute, Inc. Compounds for the treatment of mycobacterial infections
EP2765860B1 (en) 2011-10-13 2016-08-17 Merck Sharp & Dohme Corp. Mineralocorticoid receptor antagonists
EP2768517A4 (en) 2011-10-17 2015-03-11 Enanta Pharm Inc HEPATITIS C-VIRUS HEMMER
WO2013074387A1 (en) 2011-11-14 2013-05-23 Merck Sharp & Dohme Corp. Imidazole derivatives
CA2859604C (en) 2011-12-21 2019-12-17 Ono Pharmaceutical Co., Ltd. Compounds
MY170524A (en) 2012-02-02 2019-08-09 Idorsia Pharmaceuticals Ltd 4-(benzoimidazol-2-yl)-thiazole compounds and related aza derivatives
EP2647628A1 (en) 2012-04-02 2013-10-09 Almirall, S.A. Substituted tricyclic compounds with activity towards ep1 receptors
TWI610916B (zh) 2012-08-03 2018-01-11 廣東東陽光藥業有限公司 作爲丙型肝炎抑制劑的橋環化合物及其在藥物中的應用
TW201412709A (zh) 2012-09-28 2014-04-01 Sunshine Lake Pharma Co Ltd 作為丙型肝炎抑制劑的螺環化合物及其在藥物中的應用
US9047780B2 (en) 2012-11-16 2015-06-02 Robert Bosch Gmbh Collision mitigation systems and methods using driver attentiveness
EP2925533A4 (en) 2012-11-21 2016-10-12 Pooi Nguon Lim INFORMATION MEDIUM AND METHOD FOR THE MANUFACTURE THEREOF
TW201439084A (zh) 2012-11-29 2014-10-16 Sunshine Lake Pharma Co Ltd 作爲丙型肝炎抑制劑的螺環化合物、藥物組合物及它們在藥物中的應用
CN103880823B (zh) 2012-12-21 2017-12-05 广东东阳光药业有限公司 作为丙型肝炎抑制剂的螺环化合物及其在药物中的应用
CA2899402A1 (en) 2013-02-13 2014-08-21 Sumitomo Chemical Company, Limited Pest controlling composition and use thereof
CA2902858A1 (en) 2013-02-28 2014-09-04 Signal Pharmaceuticals, Llc Treatment of cancer with tor kinase inhibitors
US9944644B2 (en) 2013-03-14 2018-04-17 The Trustees Of Columbia University In The City Of New York Octahydropyrrolopyrroles their preparation and use
TWI527811B (zh) * 2013-05-09 2016-04-01 吉李德科學股份有限公司 作爲溴結構域抑制劑的苯並咪唑衍生物
CN111116563B (zh) 2013-06-06 2023-07-04 上海爱博医药科技有限公司 抑制丙肝病毒的化合物、药物组合物及其应用
JP6461118B2 (ja) 2013-06-21 2019-01-30 ゼニス・エピジェネティクス・リミテッドＺｅｎｉｔｈ Ｅｐｉｇｅｎｅｔｉｃｓ Ｌｔｄ． ブロモドメイン阻害剤としての新規の置換された二環式化合物
US9586944B2 (en) 2013-07-15 2017-03-07 The Scripps Research Institute Specific targeting of RNA expanded repeat sequences
US9795687B2 (en) 2013-08-29 2017-10-24 The Scripps Research Institute Modularly assembled small molecules for the treatment of myotonic dystrophy type 1
US9920014B2 (en) 2013-09-19 2018-03-20 The Florida International University Board Of Trustees Selective inhibition of bacterial topoisomerase I
BR112016007891A2 (pt) 2013-10-11 2017-12-05 Constellation Pharmaceuticals Inc uso de inibidores de bromodomínio cbp/ep300 para imunoterapia do câncer
JP6217317B2 (ja) 2013-10-30 2017-10-25 株式会社リコー 色素増感太陽電池
CN104610272B (zh) 2013-11-05 2017-03-29 上海唐润医药科技有限公司 环状黄酮或异黄酮类化合物及其用途
CN103728294B (zh) 2013-12-17 2016-05-11 中国科学院化学研究所 二苯并咪唑联咔唑类化合物在用于特异性结合核酸g-四链体结构及在抗肿瘤药物中的应用
WO2015110048A1 (en) 2014-01-23 2015-07-30 Sunshine Lake Pharma Co., Ltd. Bridged ring compounds as hepatitis c virus inhibitors, pharmaceutical compositions and uses thereof
CN103952009B (zh) 2014-05-08 2015-12-30 中国工程物理研究院化工材料研究所 一种近红外宽光谱金属配合物染料及其制备方法
PL408251A1 (pl) 2014-05-19 2015-11-23 Celon Pharma Spółka Z Ograniczoną Odpowiedzialnością Skondensowane pochodne triazolu jako inhibitory fosfodiesterazy 10A
CN104030988B (zh) 2014-06-25 2016-07-06 上海道亦化工科技有限公司 一种基于苯并咪唑的电子传输化合物
CN104193738B (zh) 2014-08-21 2016-05-18 上海道亦化工科技有限公司 一种基于苯并咪唑的电子传输化合物
JP2017529358A (ja) 2014-09-19 2017-10-05 ジェネンテック， インコーポレイテッド がんの処置のためのｃｂｐ／ｅｐ３００阻害剤およびｂｅｔ阻害剤の使用
US20190055235A1 (en) 2014-12-17 2019-02-21 Zenith Epigenetics Ltd. Substituted bicyclic compounds as bromodomain inhibitors
CN107406438B (zh) 2014-12-17 2021-05-14 恒翼生物医药科技(上海)有限公司 溴结构域的抑制剂
CN104710410B (zh) 2015-01-23 2017-10-10 固安鼎材科技有限公司 一种联苯并咪唑衍生物、其制备方法及其应用
GB201506660D0 (en) 2015-04-20 2015-06-03 Cellcentric Ltd Pharmaceutical compounds

Also Published As

Publication number Publication date
US10118920B2 (en) 2018-11-06
JP6871864B2 (ja) 2021-05-19
EP3286183A1 (en) 2018-02-28
ES2888473T3 (es) 2022-01-04
DK3286183T3 (da) 2021-09-20
WO2016170324A1 (en) 2016-10-27
JP2018519249A (ja) 2018-07-19
US20180127402A1 (en) 2018-05-10
CN107750249A (zh) 2018-03-02
EP3286183B1 (en) 2021-08-25
GB201506658D0 (en) 2015-06-03

Similar Documents

Publication Publication Date Title
HUE056334T2 (hu) Izoxazolil-lal szubsztituált benzimidazolok
IL250464A0 (en) injection devices
GB201620683D0 (en) Early entry
PL3360173T3 (pl) Architektura urządzenia
GB201610586D0 (en) Early entry
GB201602284D0 (en) Early entry
GB2532300B (en) Injection devices
GB201501297D0 (en) Device
HUE044646T2 (hu) Izoxazolil-lal szubsztituált imidazopiridinek
GB201507294D0 (en) Early Entry
GB201414798D0 (en) Injection devices
HK1247061A1 (zh) 改進的垂直滑動衣物懸掛裝置
GB201518811D0 (en) Early entry
GB2537033B (en) Device
SG11201802854PA (en) Device arrangement
IL250306A0 (en) indazoles
GB201515777D0 (en) Device
HK1247165A1 (zh) 負載捆扎裝置
GB201521136D0 (en) Device
GB201519583D0 (en) Device
GB201520365D0 (en) Early entry
GB201621441D0 (en) Early entry
GB201512746D0 (en) Early entry
GB201513473D0 (en) Device
GB201516402D0 (en) Early Entry